International Review of Ophthalmology ›› 2012, Vol. 36 ›› Issue (1): 21-25.doi: 10-3760/ cma.j.issn.1673-5803.2012.01.005
Previous Articles Next Articles
LI Rong, WANG Yu-sheng
Received:
Online:
Published:
Contact:
Abstract: Evidencebased medicine is very important to clinical prevention and treatment for retinopathy of prematurity(ROP). Although retianl ablation including cryotherapy and laser has been proved to be effective in treating ROP, it can be destructive to the peripheral retina to some extent. Therefore, better and safer therapies are desired. After the two influential clinical trials—“Cryotherapy forretinopathy of prematurity(CRYO-ROP)” and “Early treatment for retinopathy of prematurity study(ET\|ROP)”, other significant multicenter clinical trials has been initiated successively in the United States in order to explore novel therapeutic ways, such as ”The effects of light reduction on retinopathy of prematurity(LIGHT-ROP)”,“Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity(STOP-ROP)”and ” Bevacizumab eliminates the angiogenic threat of retinopathy of prematurity(BEAT-ROP)”. In this article, we reviewed the goals, designs, main results and conclusions of the three trials.
LI Rong, WANG Yu-sheng. Introduction of multicenter clinical trials for retinopathy of retinopathy: LIGHT-ROP, STOP-ROP and BEAT-ROP[J]. International Review of Ophthalmology, 2012, 36(1): 21-25.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.j-bio.net/EN/10-3760/ cma.j.issn.1673-5803.2012.01.005
http://www.j-bio.net/EN/Y2012/V36/I1/21